Literature DB >> 23083789

Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.

Brian A Ference1, Wonsuk Yoo, Issa Alesh, Nitin Mahajan, Karolina K Mirowska, Abhishek Mewada, Joel Kahn, Luis Afonso, Kim Allan Williams, John M Flack.   

Abstract

OBJECTIVES: The purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipoprotein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).
BACKGROUND: LDL-C is causally related to the risk of CHD. However, the association between long-term exposure to lower LDL-C beginning early in life and the risk of CHD has not been reliably quantified.
METHODS: We conducted a series of meta-analyses to estimate the effect of long-term exposure to lower LDL-C on the risk of CHD mediated by 9 polymorphisms in 6 different genes. We then combined these Mendelian randomization studies in a meta-analysis to obtain a more precise estimate of the effect of long-term exposure to lower LDL-C and compared it with the clinical benefit associated with the same magnitude of LDL-C reduction during treatment with a statin.
RESULTS: All 9 polymorphisms were associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C, with no evidence of heterogeneity of effect (I(2) = 0.0%). In a meta-analysis combining nonoverlapping data from 312,321 participants, naturally random allocation to long-term exposure to lower LDL-C was associated with a 54.5% (95% confidence interval: 48.8% to 59.5%) reduction in the risk of CHD for each mmol/l (38.7 mg/dl) lower LDL-C. This represents a 3-fold greater reduction in the risk of CHD per unit lower LDL-C than that observed during treatment with a statin started later in life (p = 8.43 × 10(-19)).
CONCLUSIONS: Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in the risk of CHD than the current practice of lowering LDL-C beginning later in life.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23083789     DOI: 10.1016/j.jacc.2012.09.017

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  201 in total

1.  Association of Maternal Prepregnancy Dyslipidemia With Adult Offspring Dyslipidemia in Excess of Anthropometric, Lifestyle, and Genetic Factors in the Framingham Heart Study.

Authors:  Michael M Mendelson; Asya Lyass; Christopher J O'Donnell; Ralph B D'Agostino; Daniel Levy
Journal:  JAMA Cardiol       Date:  2016-04-01       Impact factor: 14.676

Review 2.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.

Authors:  Ashwin Durairaj; Alberto Sabates; Jonathan Nieves; Brian Moraes; Seth Baum
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

Review 3.  New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease.

Authors:  Julius L Katzmann; Ulrich Laufs
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

4.  Beyond Framingham and coronary calcium: predicted lifetime risk identifies unfavorable risk trajectories.

Authors:  Andre R M Paixao; Jarett D Berry
Journal:  J Nucl Cardiol       Date:  2013-12-20       Impact factor: 5.952

5.  [New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Authors:  G Klose; F U Beil; H Dieplinger; A von Eckardstein; B Föger; I Gouni-Berthold; W Koenig; G M Kostner; U Landmesser; U Laufs; F Leistikow; W März; M Merkel; D Müller-Wieland; G Noll; K G Parhofer; B Paulweber; W Riesen; J R Schaefer; E Steinhagen-Thiessen; A Steinmetz; H Toplak; C Wanner; E Windler
Journal:  Internist (Berl)       Date:  2014-05       Impact factor: 0.743

Review 6.  Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.

Authors:  Michael V Holmes; Mika Ala-Korpela; George Davey Smith
Journal:  Nat Rev Cardiol       Date:  2017-06-01       Impact factor: 32.419

Review 7.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

8.  Patterns and predictors of medication adherence to lipid-lowering therapy in children aged 8 to 20 years.

Authors:  Nina R Joyce; Gregory A Wellenius; Charles B Eaton; Amal N Trivedi; Justin P Zachariah
Journal:  J Clin Lipidol       Date:  2016-03-10       Impact factor: 4.766

Review 9.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

Review 10.  The role of early LDL lowering to prevent the onset of atherosclerotic disease.

Authors:  Brian A Ference; Nitin Mahajan
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.